NYSE:ZTS (USA) Also trade in: Germany Mexico UK

Zoetis Inc

$ 101.97 -0.96 (-0.93%)
Volume: 2,042,107 Avg Vol (1m): 1,929,177
Market Cap $: 48.81 Bil Enterprise Value $: 53.46 Bil
P/E (TTM): 35.65 P/B: 21.26
Earnings Power Value 16.6
Net Current Asset Value -8.67
Tangible Book -4.54
Projected FCF 25.56
Median P/S Value 60.83
Graham Number 0
Peter Lynch Value 61.92
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.28
Cash-To-Debt ranked lower than
78.58% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
ZTS: 0.28
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.09, Med: 0.16, Max: 4.34
Current: 0.28
0.09
4.34
Equity-to-Asset 0.21
Equity-to-Asset ranked lower than
90.86% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
ZTS: 0.21
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.12, Med: 0.2, Max: 0.69
Current: 0.21
0.12
0.69
Debt-to-Equity 2.78
Debt-to-Equity ranked lower than
96.31% of 596 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
ZTS: 2.78
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.02, Med: 2.85, Max: 5.14
Current: 2.78
0.02
5.14
Debt-to-EBITDA 2.91
Debt-to-EBITDA ranked lower than
57.98% of 495 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
ZTS: 2.91
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 0.08, Med: 2.73, Max: 5.61
Current: 2.91
0.08
5.61
Interest Coverage 8.60
Interest Coverage ranked lower than
70.06% of 648 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
ZTS: 8.6
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 7.26, Med: 8.53, Max: 26.77
Current: 8.6
7.26
26.77
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 5.34
DISTRESS
GREY
SAFE
Beneish M-Score -2.52
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 24.41%
WACC 5.83%

Profitability & Growth : 7/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 31.25
Operating Margin ranked higher than
95.13% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
ZTS: 31.25
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 7.79, Med: 19.7, Max: 32.5
Current: 31.25
7.79
32.5
Net Margin % 23.47
Net Margin ranked higher than
87.03% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
ZTS: 23.47
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -3.62, Med: 10.56, Max: 24.52
Current: 23.47
-3.62
24.52
ROE % 65.78
ROE ranked higher than
98.08% of 832 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
ZTS: 65.78
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 6.58, Med: 28.5, Max: 72.21
Current: 65.78
6.58
72.21
ROA % 14.05
ROA ranked higher than
86.57% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
ZTS: 14.05
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: 4.16, Med: 7.86, Max: 14.75
Current: 14.05
4.16
14.75
ROC (Joel Greenblatt) % 59.08
ROC (Joel Greenblatt) ranked higher than
90.88% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
ZTS: 59.08
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 16.99, Med: 29.85, Max: 61.8
Current: 59.08
16.99
61.8
3-Year Total Revenue Growth Rate 6.90
3-Year Revenue Growth Rate ranked lower than
55.01% of 689 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 291.9, Med: 5.8, Min: -100
ZTS: 8
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 2.5, Med: 4.1, Max: 16.3
Current: 8
2.5
16.3
3-Year Total EBITDA Growth Rate 36.40
3-Year EBITDA Growth Rate ranked higher than
72.87% of 704 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
ZTS: 37.8
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -2.8, Med: 21.4, Max: 677.8
Current: 37.8
-2.8
677.8
3-Year EPS w/o NRI Growth Rate 62.70
3-Year EPS w/o NRI Growth Rate ranked higher than
61.09% of 663 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
ZTS: 62.7
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 14.7, Max: 62.7
Current: 62.7
0
62.7

» ZTS's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:ZTS

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare NYSE:AGN XTER:MRK SHSE:600276 TSE:4502 TSE:4507 TSX:WEED XTAE:TEVA TSE:4523 NSE:SUNPHARMA NAS:MYL SZSE:000538 NYSE:ELAN SZSE:300122 SHSE:600196 SHSE:600332 XPAR:IPN TSX:ACB HKSE:03320 TSE:4506 XSWX:VIFN
Traded in other countries ZOE.Germany 0M3Q.UK
Address 10 Sylvan Way, Parsippany, NJ, USA, 07054
Zoetis Inc sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns the majority of its revenue from production animals (cattle, pigs, poultry, and so on) but also sells companion animal (dogs, horses, cats) products. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Ratios

Current vs industry vs history
PE Ratio (TTM) 35.65
PE Ratio ranked lower than
73.97% of 557 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1910, Med: 23.77, Min: 0.06
ZTS: 35.65
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 27.31, Med: 37.91, Max: 133.08
Current: 35.65
27.31
133.08
Forward PE Ratio 29.67
Forward P/E ranked lower than
76.58% of 111 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
ZTS: 29.67
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 35.65
PE without NRI ranked lower than
73.38% of 556 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 2125, Med: 24.2, Min: 0.06
ZTS: 35.65
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 27.31, Med: 37.91, Max: 133.08
Current: 35.65
27.31
133.08
Price-to-Owner-Earnings 31.96
Price-to-Owner-Earnings ranked lower than
50.31% of 324 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 3160, Med: 31.95, Min: 0.17
ZTS: 31.96
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 25.56, Med: 56.43, Max: 271.57
Current: 31.96
25.56
271.57
PB Ratio 21.26
PB Ratio ranked lower than
97.56% of 819 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
ZTS: 21.26
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 12.62, Med: 18.47, Max: 24.4
Current: 21.26
12.62
24.4
PS Ratio 8.37
PS Ratio ranked lower than
78.32% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
ZTS: 8.37
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 3.11, Med: 4.99, Max: 8.51
Current: 8.37
3.11
8.51
Price-to-Free-Cash-Flow 34.29
Price-to-Free-Cash-Flow ranked lower than
50.67% of 298 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 3143.75, Med: 30.84, Min: 0.23
ZTS: 34.29
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 25.69, Med: 45.5, Max: 90.56
Current: 34.29
25.69
90.56
Price-to-Operating-Cash-Flow 27.63
Price-to-Operating-Cash-Flow ranked lower than
60.20% of 392 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
ZTS: 27.63
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 21.62, Med: 31.23, Max: 41.95
Current: 27.63
21.62
41.95
EV-to-EBIT 28.60
EV-to-EBIT ranked lower than
68.36% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
ZTS: 28.6
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 20.2, Med: 25.1, Max: 41.6
Current: 28.6
20.2
41.6
EV-to-EBITDA 24.14
EV-to-EBITDA ranked lower than
70.52% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
ZTS: 24.14
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 16.5, Med: 21, Max: 32.1
Current: 24.14
16.5
32.1
EV-to-Revenue 9.04
EV-to-Revenue ranked lower than
76.23% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
ZTS: 9.04
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 3.8, Med: 5.7, Max: 9.3
Current: 9.04
3.8
9.3
PEG Ratio 1.80
PEG Ratio ranked lower than
61.51% of 317 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1472, Med: 1.93, Min: 0.07
ZTS: 1.8
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 1.35, Med: 2.66, Max: 3.29
Current: 1.8
1.35
3.29
Current Ratio 4.05
Current Ratio ranked higher than
72.98% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
ZTS: 4.05
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.96, Med: 2.86, Max: 4.38
Current: 4.05
1.96
4.38
Quick Ratio 2.79
Quick Ratio ranked higher than
66.08% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
ZTS: 2.79
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.07, Med: 1.69, Max: 2.92
Current: 2.79
1.07
2.92
Days Inventory 259.81
Days Inventory ranked lower than
91.26% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
ZTS: 259.81
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 125.75, Med: 281.16, Max: 325.24
Current: 259.81
125.75
325.24
Days Sales Outstanding 59.87
Days Sales Outstanding ranked higher than
66.36% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
ZTS: 59.87
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 59.87, Med: 74.75, Max: 91.07
Current: 59.87
59.87
91.07
Days Payable 43.28
Days Payable ranked lower than
73.61% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
ZTS: 43.28
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 43.28, Med: 59.78, Max: 110.66
Current: 43.28
43.28
110.66

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 0.57
Trailing Dividend Yield ranked lower than
85.77% of 752 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 25.84, Med: 1.54, Min: 0.04
ZTS: 0.57
Ranked among companies with meaningful Trailing Dividend Yield only.
Trailing Dividend Yield range over the past 10 years
Min: 0.21, Med: 0.65, Max: 1.08
Current: 0.57
0.21
1.08
Dividend Payout Ratio 0.19
Dividend Payout Ratio ranked higher than
78.20% of 477 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 68, Med: 0.3, Min: 0.02
ZTS: 0.19
Ranked among companies with meaningful Dividend Payout Ratio only.
Dividend Payout Ratio range over the past 10 years
Min: 0.17, Med: 0.24, Max: 0.49
Current: 0.19
0.17
0.49
3-Year Dividend Growth Rate (Per Share) 14.90
3-Year Dividend Growth Rate ranked higher than
65.55% of 299 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 114, Med: 7.4, Min: -100
ZTS: 14.9
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
3-Year Dividend Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: 24.9
Current: 14.9
0
24.9
Forward Dividend Yield % 0.64
Forward Dividend Yield ranked lower than
85.67% of 719 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 25.84, Med: 1.66, Min: 0.04
ZTS: 0.64
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield-on-Cost (5-Year) % 1.35
Yield-on-Cost (5y) ranked lower than
85.91% of 745 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 42.46, Med: 2.12, Min: 0.03
ZTS: 1.35
Ranked among companies with meaningful Yield-on-Cost (5y) only.
Yield-on-Cost (5y) range over the past 10 years
Min: 0.5, Med: 1.54, Max: 2.56
Current: 1.35
0.5
2.56
3-Year Share Buyback Rate 1.20
3-Year Share Buyback Rate ranked higher than
93.17% of 571 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 100, Med: -5.3, Min: -815
ZTS: 1.2
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -0.1, Med: 0.2, Max: 1.2
Current: 1.2
-0.1
1.2

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 3.99
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
79.68% of 374 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 209, Med: 2.11, Min: 0.05
ZTS: 3.99
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 3.51, Med: 4.41, Max: 5.27
Current: 3.99
3.51
5.27
Price-to-Median-PS-Value 1.67
Price-to-Median-PS-Value ranked lower than
82.23% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
ZTS: 1.67
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.64, Med: 1.01, Max: 1.67
Current: 1.67
0.64
1.67
Price-to-Peter-Lynch-Fair-Value 1.65
Price-to-Peter-Lynch-Fair-Value ranked lower than
71.23% of 212 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 26.42, Med: 1.41, Min: 0.08
ZTS: 1.65
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 1.42, Med: 2.62, Max: 3.18
Current: 1.65
1.42
3.18
Earnings Yield (Joel Greenblatt) % 3.50
Earnings Yield (Greenblatt) ranked higher than
54.79% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
ZTS: 3.5
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 2.4, Med: 4, Max: 5
Current: 3.5
2.4
5
Forward Rate of Return (Yacktman) % 21.62
Forward Rate of Return ranked higher than
76.48% of 421 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 559.55, Med: 8.96, Min: -1635.32
ZTS: 21.62
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: 12.8, Med: 16.1, Max: 22
Current: 21.62
12.8
22

More Statistics

Revenue (TTM) (Mil) $ 5,914
EPS (TTM) $ 2.86
Beta 0.64
Volatility % 15.72
52-Week Range $ 78.9 - 103.97
Shares Outstanding (Mil) 478.66

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy Y
Higher Gross Margin yoy N
Higher Asset Turnover yoy N